Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flutrimazole is a broad-spectrum imidazole antifungal drug used topically for the treatment of superficial mycoses of the skin, including conditions such as pityriasis capitis, seborrheic dermatitis, athlete’s foot (tinea pedis), tinea corporis and cruris, tinea versicolor, onychomycosis, facial tinea, and vulvitis. Its mechanism of action involves inhibition of fungal lanosterol 14α-demethylase (a sterol demethylase), which disrupts ergosterol biosynthesis in the fungal cell membrane. This leads to increased membrane permeability and ultimately cell death. The drug demonstrates efficacy comparable to clotrimazole and superior to bifonazole in clinical studies. It has minimal systemic absorption when applied topically and is well tolerated with a favorable safety profile[1][2][3][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flutrimazole.